To study effect of telmisartan on hypertension

Objectives: Elevated blood pressure in the early morning is associated with increased cardiovascular risk. It is crucial that antihypertensive medication controls blood pressure to minimize this risk at this time. The ARB with the longest half-life is telmisartan. Its potential to reduce blood pressure in the risky early morning hours has been demonstrated in numerous clinical studies using Ambulatory blood pressure monitoring. Material and Methods: This study was conducted during the period from the December 2016 until the end of November 2019 in Muzaffarnagar Medical College, Muzaffarnagar, U.P., India.. A total of 100 subjects of hypertension who were treated with telmisartan 40 mg for six weeks having an age group of 40-65 years were included. Result: The results show comparison of blood pressure between without treatment and with telmisartan 40 mg for six weeks. The mean levels of SBP and DBP in control group without treatment were 176.14 ± 12.06 mmHg and 94.26 ± 8.32 mmHg. On the other hand in study group with telmisartan 40 mg for six weeks subjects were 128.08 ± 10.18 and 84.22 ± 6.14 respectively. It is evident from data that telmisartan 40 mg significantly decreased blood pressure. Conclusions: Angiotensin receptor blocker (ARBs) like telmisartan has been used to normalize the blood pressure. Further studies with large number of subjects with longer duration of follow-up are required to validate these observations.